Nabriva Therapeutics Forschungs GMBH
This article was originally published in Start Up
Executive Summary
In January, Sandoz spun out Nabriva Therapeutics to initiate clinical development of three classes of antibiotics. Using medicinal chemistry, Sandoz had created thousands of compounds derived from intermediates used in the manufacture of generic antibiotics, which were themselves active against bacteria.
You may also be interested in...
The A-List: 2006's Trend-Shaping Series A Financings
2006's most intriguing Series As reflect VCs' continued emphasis on risk reduction through reprofiling in biotech, and big gains in funding for diagnostics and device start-ups.
The A-List: 2006's Trend-Shaping Series A Financings
2006's most intriguing Series As reflect VCs' continued emphasis on risk reduction through reprofiling in biotech, and big gains in funding for diagnostics and device start-ups.
Antibacterial Drug Development
For some start-ups, keeping pace with Big Pharma's shifting business priorities means following a path of less resistance. New companies are being formed around Big Pharma assets that no longer fit their priorities and market needs; others are fueled by novel discovery approaches based on elucidating and harnessing the power of natural genetic mechanisms.